First Manhattan’s NeoGenomics NEO Stock Holding History

First Manhattan’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-21	Closed	-$258	–	1525
2023 Q3	$258	Buy	+21	New	+$312	﹤0.01%	1412

Other funds holding NEO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Greenhouse Funds Baltimore, Maryland $2.23B AUM 12.38% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

First Manhattan's NEO Position: Q4 2023 in Review

First Manhattan sold out of NeoGenomics (NEO) in Q4 2023, closing a stake of 21 shares — an estimated $258 sold.

First Manhattan first reported a position in NEO in Q3 2023 and held it in 1 quarter. The position peaked at $258 in Q3 2023. 287 funds tracked by Wall St. Rank hold NEO as of Q4 2023.

First Manhattan reported no remaining NeoGenomics position as of Q4 2023 after selling out during the quarter.
First Manhattan sold 21 NeoGenomics shares in Q4 2023, an estimated $258.
First Manhattan first reported a position in NeoGenomics in Q3 2023 and held it in 1 quarter.
First Manhattan's NeoGenomics position peaked at $258 in Q3 2023.
287 funds tracked by Wall St. Rank held NeoGenomics as of Q4 2023.

Based on First Manhattan's 13F filing for Q4 2023, filed 13 Feb 2024.